2026 年 1 月 26 日
“Once you enter clinical development, the probability of actually getting an approved compound is about ten percent. Ninety percent of drugs that enter the clinic fail for multiple reasons.”
“At the core is the data on the compound and the program itself, but many other elements come into play: team expertise, infrastructure, development plans, risk mitigation, commercial potential, and intellectual property.”
“MIDD turns good data into predictive data, showing that what you have seen is not just plausible but quantitatively reproducible through modeling and simulation.”
“With modeling we can reconstruct the exposure-response relationship even when raw datasets are not available and then simulate different dosing and population scenarios to quantify risk.”
To hear the full conversation and see real examples of how MIDD and virtual evaluation are being used to strengthen asset valuation, accelerate partnering, and guide development decisions, view the on-demand webinar featuring Fran Brown and Amy Cheung.
Erika Brooks
Marketing Director, Quantitative Science ServicesWith over 22 years of experience in hospitals, health systems, associations, life sciences, physician practices, and suppliers, Erika is an experienced marketing strategist and supports the Quantitative Science Services offering with Go-to market planning and execution.
Vice President, Europe/APAC Regional Lead of Quantitative Science, Global Lead of Certara’s Pediatric and Maternal Innovation Engine
Dr. Cheung has more than 20 years of experience in modeling and simulation, as well as clinical pharmacology, with expertise in PBPK/PD mechanistic modelling, special populations (e.g., pediatrics, maternal, and geriatrics), extrapolation, model-based meta-analysis, vaccines, infections, HIV, complex biologics, and different therapeutic areas across early, late-phase and post marketing drug development. She is an honorary professor at the School of Engineering at the University of Warwick, UK. She is leading the EU funding project, ERAMET (grant agreement number 101137141), in work package 5, championing the enhancement and utilization of extrapolation in pediatric populations and for rare diseases.
Vice President, Global Head, Drug Development Science
Dr. Fran Brown is a highly respected professional with proven leadership skills and 28 years of broad experience within pharmaceutical development and due diligence. She has extensive experience with strategic and operational global drug development from early discovery to filing and post-marketing. This experience spans multiple therapeutic areas, small molecules and biologics, global regulatory requirements and registration pathways. She possesses a broad knowledge of product development and portfolio management, with a special focus on development strategy, regulatory interactions and product filings.
联系我们
